Blurbs

Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), Adicet Bio (ACET) and MiNK Therapeutics (INKT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on scPharmaceuticals (SCPHResearch Report), Adicet Bio (ACETResearch Report) and MiNK Therapeutics (INKTResearch Report) with bullish sentiments.

scPharmaceuticals (SCPH)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on scPharmaceuticals, with a price target of $10.00. The company’s shares closed last Wednesday at $5.82.

According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -30.1% and a 24.6% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Clarus Therapeutics Holdings, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for scPharmaceuticals with a $10.33 average price target.

See the top stocks recommended by analysts >>

Adicet Bio (ACET)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Adicet Bio today and set a price target of $34.00. The company’s shares closed last Wednesday at $17.95.

According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -16.3% and a 31.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Currently, the analyst consensus on Adicet Bio is a Strong Buy with an average price target of $28.50.

MiNK Therapeutics (INKT)

H.C. Wainwright analyst Emily Bodnar initiated coverage with a Buy rating on MiNK Therapeutics today and set a price target of $7.00. The company’s shares closed last Wednesday at $1.33, close to its 52-week low of $1.09.

According to TipRanks.com, Bodnar is a 3-star analyst with an average return of 3.3% and a 50.0% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as TransCode Therapeutics, Olema Pharmaceuticals, and Context Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MiNK Therapeutics with a $7.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SCPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More